With King in its fold, Pfizer — which makes Lyrica and Celebrex — believes it can build an industry-leading portfolio of pain relievers. Among King’s most appealing entrants in that market is the new Embeda, designed to preve…
Regardless of where the index stands, since the Dow gets so much attention, it’s interesting to note how its components are pushing and pulling on the measure. Let’s look at how the various component stocks are performing.
…
There’s a new plot twist in the takeover battle between French pharmaceutical giant Sanofi-Aventis and U.S. drugmaker Genzyme. A regulatory filing made by Genzyme on Thursday claims Sanofi may be willing to go much higher than …
Global pharmaceutical sales are expected to grow by 5% to 7% in 2011, thanks to robust growth in emerging markets, especially China, as well as new innovative treatments, and despite patent expirations and budget pressures in t…
Its total worldwide costs for 2010 are estimated to be $604 billion, or around 1% of the world’s GDP, according to World Alzheimer Report 2010 from Alzheimer’s Disease International. By 2030, that burden could hit more than $1….